Local control and radionecrosis of brain metastases from non-small-cell lung cancer treated by hypofractionated stereotactic radiotherapy: Evaluation of predictive factors.
Brain metastases
Local control
Multifractionated stereotactic radiotherapy
Non-small-cell lung cancer
Radionecrosis
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
30
11
2021
revised:
30
05
2022
accepted:
30
05
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
24
6
2022
Statut:
epublish
Résumé
The objective of our study was to report predictive factors of local control (LC) and radionecrosis (RN) of brain metastases (BM) of non-small cell lung carcinoma (NSCLC) treated by multifractionated stereotactic radiotherapy (MF-SRT) according to French recommendations. From 2012 to 2020, 87 patients with 101 BM were retrospectively included. The median age was 63 years (37-85). GTV was defined using contrast-enhanced T1w MRI and was isotropically extended by 2 mm to form PTV. Mean maximum BM diameter was 24.5 mm (10-46). Patients were treated with dynamic arctherapy from May 2012 to February 2016 and then with VMAT. The total prescribed dose was 23.1 Gy prescribed to the encompassing 70% isodose, in 3 fractions. LC rates at 6 months, 1 year and 2 years was 95.7%, 90.7% and 87.9% respectively. In multivariate analysis, high GTV Dmin (HR = 0.822, p = 0.012) was in favor of better LC whereas a large maximum diameter was predictive of poor LC (HR = 1.124, p = 0.02). GTV Dmin of 27.4 Gy was identified as a discriminant threshold of LC. In case of GTV Dmin ≥ 27.4 Gy, LC at 1 year was 95.3% versus 75.1% with GTV Dmin < 27.4 Gy. Cumulative incidence of RN at 6 months, 1 year and 2 years was 6.3%, 15.4% and 18.1%, respectively. In multivariate analysis, only dyslipidemia was predictive of RN (HR = 2.69, p = 0.03). No dosimetric predictive factor of RN was found in our study. MF-SRT (3x7.7 Gy on 70% isodose line, with PTV = GTV + 2 mm; according to French recommendations) of BM from NSCLC gives high LC rates with acceptable RN rate. A GTV Dmin of at least 27.4 Gy could be proposed to optimize dosimetric objectives. No dosimetric predictive factors of RN were found in this study. However, dyslipidemia was identified as a potential predictive factor of RN.
Sections du résumé
Background
UNASSIGNED
The objective of our study was to report predictive factors of local control (LC) and radionecrosis (RN) of brain metastases (BM) of non-small cell lung carcinoma (NSCLC) treated by multifractionated stereotactic radiotherapy (MF-SRT) according to French recommendations.
Method
UNASSIGNED
From 2012 to 2020, 87 patients with 101 BM were retrospectively included. The median age was 63 years (37-85). GTV was defined using contrast-enhanced T1w MRI and was isotropically extended by 2 mm to form PTV. Mean maximum BM diameter was 24.5 mm (10-46). Patients were treated with dynamic arctherapy from May 2012 to February 2016 and then with VMAT. The total prescribed dose was 23.1 Gy prescribed to the encompassing 70% isodose, in 3 fractions.
Results
UNASSIGNED
LC rates at 6 months, 1 year and 2 years was 95.7%, 90.7% and 87.9% respectively. In multivariate analysis, high GTV Dmin (HR = 0.822, p = 0.012) was in favor of better LC whereas a large maximum diameter was predictive of poor LC (HR = 1.124, p = 0.02). GTV Dmin of 27.4 Gy was identified as a discriminant threshold of LC. In case of GTV Dmin ≥ 27.4 Gy, LC at 1 year was 95.3% versus 75.1% with GTV Dmin < 27.4 Gy. Cumulative incidence of RN at 6 months, 1 year and 2 years was 6.3%, 15.4% and 18.1%, respectively. In multivariate analysis, only dyslipidemia was predictive of RN (HR = 2.69, p = 0.03). No dosimetric predictive factor of RN was found in our study.
Conclusion
UNASSIGNED
MF-SRT (3x7.7 Gy on 70% isodose line, with PTV = GTV + 2 mm; according to French recommendations) of BM from NSCLC gives high LC rates with acceptable RN rate. A GTV Dmin of at least 27.4 Gy could be proposed to optimize dosimetric objectives. No dosimetric predictive factors of RN were found in this study. However, dyslipidemia was identified as a potential predictive factor of RN.
Identifiants
pubmed: 35733828
doi: 10.1016/j.ctro.2022.05.008
pii: S2405-6308(22)00045-3
pmc: PMC9207219
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-8Informations de copyright
© 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Radiat Oncol. 2011 May 15;6:48
pubmed: 21575163
Cancer. 2002 May 15;94(10):2698-705
pubmed: 12173339
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1142-8
pubmed: 27209508
Expert Rev Neurother. 2016 Aug;16(8):903-14
pubmed: 27177183
Arch Neurol. 1988 Jul;45(7):741-4
pubmed: 3390029
Stereotact Funct Neurosurg. 1991;57(1-2):99-105
pubmed: 1667045
Lung Cancer. 2015 Apr;88(1):108-11
pubmed: 25682925
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1179-1189
pubmed: 28974415
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):68-86
pubmed: 32921513
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):499-508
pubmed: 16517093
Cancer Radiother. 2016 Sep;20 Suppl:S80-7
pubmed: 27523410
Rev Neurol (Paris). 1992;148(6-7):477-87
pubmed: 1448668
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):996-1001
pubmed: 19783374
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):103-11
pubmed: 25182751
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1455-60
pubmed: 15956515
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
J Neurooncol. 2014 Apr;117(2):295-301
pubmed: 24488446
J Clin Neurosci. 2011 Jun;18(6):853-5
pubmed: 21511479
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):407-13
pubmed: 25084610
J Clin Oncol. 2015 Oct 20;33(30):3475-84
pubmed: 26282648
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):419-24
pubmed: 16226848
Ann Oncol. 2011 Nov;22(11):2466-2470
pubmed: 21321089
Radiother Oncol. 2021 Jan;154:260-268
pubmed: 33245944
Stereotact Funct Neurosurg. 2003;81(1-4):115-9
pubmed: 14742974
Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):342-350
pubmed: 34537313
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Radiother Oncol. 2011 Mar;98(3):292-7
pubmed: 21316787
Cancer Radiother. 2015 Feb;19(1):66-71
pubmed: 25666314
Lung Cancer. 2019 Jun;132:119-125
pubmed: 31097084
J Radiat Res. 2013 Jul 1;54(4):727-35
pubmed: 23404206
J Neurosurg. 2006 Jun;104(6):907-12
pubmed: 16776334
Am Rev Respir Dis. 1979 Nov;120(5):1025-9
pubmed: 228572
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):618-630
pubmed: 30395902
Cancer. 2020 Apr 1;126(7):1390-1406
pubmed: 31971613